Sandwich, Kent, UK, 10th October 2023 / Sciad Newswire / DLOC Biosystems has selected Discovery Park, Kent, as the location for its new biology facility. The company will set up a biology lab within Discovery Park’s thriving life science cluster to continue development of its state-of-the-art organ-on-a-chip technology and deliver accurate assay testing services to pharmaceutical companies to advance drug discovery.
DLOC Biosystems was founded to enable faster, safer and cheaper drug development. The company’s chips provide an environment where cells can grow and reorganise into tissues, providing the perfect setting for large scale, affordable drug testing. Its technology will help to enable the reduction and replacement of animal testing, by providing more accurate data on safety and efficacy than current pre-clinical testing models.
With an engineering team based in Lebanon, DLOC was looking to build a new biology team based in the UK. The company selected Discovery Park’s high-spec lab facilities just over an hour from London due to its reputation as a leading hub for life sciences and the opportunity it offers for future expansion. Discovery Park’s extensive ecosystem provides future opportunities for collaboration as well as a network of potential customers, a key consideration for life science start-ups.
Wadah Malaeb, CEO and Founder of DLOC Biosystems, commented: “We were initially interested in locating in London as it offered access to an excellent talent pool, however, the cost and availability of high-spec lab space as well as living costs for potential employees proved inhibitive. When I visited Discovery Park, I was impressed not just by the quality of the facilities available, but also by the extensive business support offered by the team. The park and its surroundings provide an ideal location to build our business and I look forward to joining the Discovery Park community.”
Chris Broom, Head of Business Development at Discovery Park, added: “We’re passionate about supporting the transformation of ideas into successful commercial innovation. As well as access to our cutting-edge facilities, DLOC will have the opportunity to network and collaborate with our community of innovative start-ups and established companies. We are excited to welcome Wadah and his team to Discovery Park and look forward to working with them to support the growth of the company and deliver significant benefits to the drug discovery industry.”
DLOC is currently recruiting a biology team leader to start and build its new team at Discovery Park and will also expand its engineering team on site. It is also participating in the Discovery Spark programme for life science start-ups to develop and refine its business offering.
For further information, please contact:
Notes for Editors
About Discovery Park
Discovery Park is a thriving life science community for visionary entrepreneurs and leaders and the ideal environment for businesses to start, scale and succeed. We offer state-of-the-art labs, modern offices and manufacturing facilities, unrivalled flexibility and comprehensive support including access to finance and a strong local talent pool. Within easy reach of London, Discovery Park spearheads Kent’s flourishing science and technology cluster. As an extension of the Golden Triangle, our location provides access to a wealth of resources and opportunities coupled with an enviable quality of life.
Discovery Park is home to 160+ companies employing around 3,100 people across a growing tenant community of dynamic start-ups through to global corporations. This includes Pfizer, which built the site’s reputation as a centre for drug discovery and discovered some of the most famous drugs in the world here. Pfizer still play a key role in the community, occupying a third of the site and employing over 1,000 scientists, technicians, regulatory professionals and business experts. Other tenants include Algaecytes, Canterbury Christ Church University, Concept Life Sciences, eXroid, Genea Biomedx, LGC, Viatris, Psyros Diagnostics, Salvensis, VisusNano and Wren Healthcare.
About DLOC Biosystems
DLOC Biosystems has developed its organ-on-a-chip technology to enable faster, safer and cheaper drug development. The company’s chips provide an environment where cells can grow and reorganise into tissues as if they were in the human body, offering the perfect environment for large-scale, affordable drug testing. This helps to understand why certain drugs have failed, to inform the development of better drugs in the future.
DLOC’s technology will help to enable the reduction and replacement of animal testing, in line with the FDA Modernization Act 2.0, providing more accurate data on safety and efficacy than current pre-clinical testing models. It also offers the opportunity to develop precision medicines by creating patient-specific testing environments to tailor drugs to an individual person or disease.
For more information, visit: https://www.dlocbiosystems.com/